CardioExchange Archive

January 5th, 2015

Selections from Richard Lehman’s Literature Review: January 5th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include metformin in patients with type 2 diabetes and kidney disease, mortality and treatment patterns among patients hospitalized with acute CV conditions during national cardiology meetings, and more.

---

November 21st, 2014

Encouraging Results For Two New Drugs For Hyperkalemia

Larry Husten, PHD

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. … Click here to read the full post on Forbes.  

---

November 9th, 2013

Yet Another Blow to Combination Renin-Angiotensin-Aldosterone System Blockade

Larry Husten, PHD

ACE inhibitors and angiotensin-receptor blockers have been found to effectively slow progression of kidney disease. It has been theorized that dual blockade of the renin-angiotensin-aldosterone system (RAAS) might prove even more beneficial, but these hopes have not been realized. Now a new trial published in the New England Journal of Medicine throws further cold water on the once-promising hypothesis. […]

---

September 1st, 2010

Long-Term Effect of Intensive BP Control in Blacks

Larry Husten, PHD

The African-American Study of Kidney Disease and Hypertension (AASK) investigated the role of intensive blood-pressure control in slowing the progression of chronic kidney disease in black patients. In the previously reported results of the randomized portion of AASK, intensive BP control had no effect on the progression of CKD. Now the AASK Collaborative Research Group reports the […]

---